Latest Adeno-associated virus Stories
Leading gene therapy Company will partner with established market leader to develop a potential new treatment paradigm for hemophilia B PHILADELPHIA, Dec.
LEVERKUSEN, Germany, June 23, 2014 /PRNewswire/ -- Bayer HealthCare (Bayer) and Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy
GULF SHORES, Ala., April 29, 2014 /PRNewswire/ -- If successful, Neuralgene's (http://www.neuralgene.com) PRCN-323 treatment
- A person in a secondary role, specifically the second most important character (after the protagonist).